Open access peer-reviewed chapter

Cryptococcus neoformans-Host Interactions Determine Disease Outcomes

Written By

Jintao Xu, Peter R. Wiliamson and Michal A. Olszewski

Submitted: October 23rd, 2018 Reviewed: December 21st, 2018 Published: March 1st, 2019

DOI: 10.5772/intechopen.83750

From the Edited Volume

Fungal Infection

Edited by Érico Silva de Loreto and Juliana Simoni Moraes Tondolo

Chapter metrics overview

884 Chapter Downloads

View Full Metrics


The fungal pathogen Cryptococcus neoformans can infect the central nervous system (CNS) and cause fatal meningoencephalitis, which accounts for an estimated 180,000 deaths per year. Cryptococcal meningoencephalitis (CM) occurs mainly in the individuals with compromised immune systems. Thus, cryptococcal disease in the CNS has been predominantly attributed to insufficient immune responses and subsequent uncontrolled fungal growth. However, evidence has emerged that an inappropriate immune response, as much as an insufficient response, may promote clinical deterioration and pathogenesis. In this chapter, we will review the different types of immune responses to C. neoformans and their contribution to tissue damage and diseases.


  • Cryptococcus neoformans
  • pathogenesis
  • immune pathology

1. Introduction

The human fungal pathogen Cryptococcus neoformans causes substantial morbidity and mortality worldwide, with an estimated 1 million infections and 180,000 deaths per year [1, 2, 3]. Although the primary route of infection is through inhalation of yeast into the lungs, fungal dissemination to the central nervous system (CNS) leads to severe meningoencephalitis that can cause death or long-lasting neurological sequelae, including memory loss, vision deficiencies, hearing and speech impairments, and motor deficits [4, 5, 6]. Treatment options for cryptococcal meningoencephalitis (CM) are limited and often unsuccessful due to the increasing development of drug resistance, the high toxicity of the antifungal drugs and the poor permeability of the blood brain barrier [7, 8, 9]. Unsuccessful treatments are often accompanied with high mortality rates up to 15% and relapse rates of 30–50% [10, 11, 12]. Thus, there is a pressing need for understanding the pathogenesis of C. neoformans infection to develop more effective therapeutic strategies.

Cryptococcal infections usually manifest in patients who are immunocompromised secondary to HIV infection, cancer therapies, or organ transplantation [3]. This has led to the characterization of C. neoformans as an “opportunistic pathogen” that causes disease only when the immune system cannot control its growth. Prior studies have established a central role for T cell mediated immunity in fungal clearance from the lungs and suggested that T-cell mediated immunity is also beneficial in the CNS [13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]. These studies also support a paradigm that clinical failures are predominantly due to a deficiency in microbiological control. However, attempts to develop immunotherapies that enhance the immune responses in CM have been largely unsuccessful, indicating other factors may also participate in the disease pathology [26]. Furthermore, clinical and experimental studies increasingly show that an exaggerated host immune response can promote cryptococcal pathogenesis. For example, a common complication of CM in HIV/AIDS patients is the immune reconstitution inflammatory syndrome (cIRIS) that develops after initiation of anti-retroviral therapy [27, 28]. A parallel syndrome occurs among non-HIV patients with severe cryptococcal CNS infection, termed post infectious immune inflammatory syndrome (PIIRS) [29, 30, 31]. These patients develop severe neurological sequela and morbidity with persisting inflammatory responses, often despite fungal eradication [28, 32, 33, 34, 35, 36]. A detrimental role of host inflammation is further supported by the therapeutic effects of corticosteroids in ameliorating IRIS and PIIRS symptoms and by observations that premature or abrupt steroid-weaning may result in the recurrence of CNS lesions and clinical relapse [29, 30, 37].

This evidence challenges the view that cryptococcal disease is a consequence of a compromised immune system. Instead, the outcomes of cryptococcal disease can be better understood as a balance of C. neoformans-host interactions. The effect of C. neoformans on host disease can be explained by the damage-response framework (DRF), a theory for microbial pathogenesis proposed in 1999 [38]. The DRF theory incorporates the contributions of host-microbe interaction, rather than presenting microbial pathogenesis as a singular outcome of either microbial factors or host factors. The results of host-microbe interaction can be visualized with a single parabola depicting host damage as a function of the strength of the immune response [26]. Weak host immune responses due to HIV infection or immunosuppressive therapies fail to control fungal growth, which results in fungus-mediated host damage. However, strong immune responses elicited by C. neoformans can also lead to host damages and diseases. In this chapter, we will review recent human clinical and experimental animal studies that have enhanced our understanding of the complex mechanisms involved in immunopathogenesis during C. neoformans infection. Uncovering the mechanisms that are involved in anticryptococcal host defense or in immunopathogenesis will facilitate the discovery of new intervention strategies to treat cryptococcal infections.


2. Cryptococcal immune reconstitution inflammatory syndrome

C. neoformans can cause infection in both the meninges and the Virchow-Robin channels surrounding the penetrating vessels within the brain parenchyma [39]. Although the exact mechanism by which this encapsulated pathogen migrates into the CNS is currently unclear, studies have found that circulating C. neoformans was trapped in the brain capillary and can actively transmigrate the microvasculature with contributions from urease and metalloprotease [40, 41, 42]. After migration, C. neoformans causes fatal meningoencephalitis which accounts for 15–20% of AIDS-related deaths [1, 43, 44]. The high fungal burdens during CM in AIDS are associated with mortality, suggesting a prominent role of the fungal pathogen for host damage [45]. Thus, in HIV infection/AIDS, susceptibility to CM is thought to occur due to lack of T cell-mediated fungal clearance. Indeed, studies have shown that presence of CSF cytokine and chemokine responses consisting primarily of IL-6, IFN-γ, IL-8, IL-10, IL-17, CCL5 and TNF-α, are associated with increased macrophage activation, more rapid fungal clearance from the CSF, and patient survival [45]. The overall low levels of cytokine production in AIDS patients and insufficient activation of resident or recruited macrophages in the absence of T cells producing IFN-γ/TNF-α lead to uncontrolled fungal growth [45, 46].

Antiretroviral therapy (ART) in AIDS patients rapidly restores host T cell responses. However, in a portion of patients it leads to a highly lethal complication, cIRIS, which is defined as a paradoxical clinical deterioration after initiation of ART, despite efficient control of fungal infection [28]. cIRIS occurs in 15–30% of HIV-infected individuals with cryptococcosis [28, 47]. Similarly, patients who undergo immune suppressive regiments during bone marrow transplantation or autoimmune diseases can develop cIRIS like syndromes once the host immune response is restored when immunosuppressive therapy is tapered [48]. Previous studies have found that paucity of initial CSF inflammation, low IFN-γ levels, and high fungal loads are risk factors for the development of IRIS [27, 45]. During cIRIS, the immune response in the brain is characterized by excessive activation of Th1 CD4+ subsets with elevated production of cytokines including IFN-γ and TNF-α [27, 33, 49].

While the exact pathogenic mechanisms of IRIS have not been unraveled, the lymphopenic environment during HIV infection may result in abnormal function of residual CD4 T cells, rendering them more pathogenic as the population expands after ART [50]. Furthermore, it has also been proposed that there exists a decoupling of innate and adaptive immune responses in AIDS patients prior to ART due to deficient T cell responses, which sets the stage for excessive inflammation after T cell reconstitution. Indeed, several lines of evidence show that mononuclear immune cells are implicated in cIRIS. Predisposition to cIRIS has been shown to be associated with higher CCL2/MCP-1, CCL3/MIP-1α, and GMCSF production in the CSF, which promotes trafficking and activation of macrophages in the infection sites [45]. Patients with cIRIS had increased numbers of proinflammatory intermediate monocytes (CD14highCD16+) which produce reactive oxygen species [51, 52]. Although macrophages can be primed by fungal pathogens in AIDS patients prior to ART, they never become fully activated in the absence of T cell help to exert their effector functions in fungal clearance. This results in high levels of pathogen replication as the disease progresses. Nevertheless, increasing numbers of primed macrophages accumulate and create a state of immunological hyperresponsiveness to the subsequently CD4+ T cell help. ART rapidly restores Th1 type response in the host with high level of IFN-γ production. Large numbers of primed macrophages then become fully activated to produce an acute spike in proinflammatory mediators, which may drive immunopathology during cIRIS. Thus, macrophage activation in cIRIS may act in concert with T-cell responses resulting in tissue-destructive inflammatory responses.

The mechanisms of tissue damage by host inflammation during fungal infections are still under active research. Macrophage or T cell production of TNF-α, IL-1β, reactive oxygen species (ROS) and nitrogen species (RNS), may contribute to irreversible tissue damage and/or lead to neuronal apoptosis [53, 54, 55]. C. neoformans infection also induces cerebral edema and raised CSF pressure that are associated with symptoms including headache, nausea, and mental status deterioration.


3. Postinfectious inflammatory response syndrome

Another example showing that strong host immune responses during C. neoformans infection can induce immunopathology is post-infectious inflammatory response syndrome (PIIRS). It is characterized in non-HIV patients during initial therapy by severe mental deficits despite antifungal therapy and their apparent immunocompetent state. Reports showed that up to 25% of cases in the United States and 60% in the Far East occur in apparently immune competent patients [56, 57]. Despite antifungal therapy and negative CSF-C. neoformans cultures, PIIRS patients many times require ventricle-peritoneal shunts to relieve the high CSF pressure caused by inflammation. Recent studies have shown that patients with PIIRS exhibit strong intrathecal Th1 responses with high levels of IFN-γ production and a relatively lack of Th2 responses [30]. Importantly, elevated levels of CSF neurofilament light chain (NFL), a marker of axonal injury, indicate ongoing immunological host neuron damage. Interestingly, macrophages recruited to the CNS infection site are often alternatively activated (M2) and exhibit poor phagocytic effect during PIIRS [30]. This apparent Th1-M2 discrepancy suggests that PIIRS patients may have downstream defects in monocyte activation. New therapies that consider immune-mediated host injury may decrease mortality in these severe or refractory clinical cases [43].


4. Animal models of IRIS and PIIRS

Detrimental roles for immune responses in the pathogenesis of cryptococcus-associated IRIS or PIIRS have also been recently demonstrated in experimental mouse models. A recent study in our lab established a reproducible mouse model of CM using C57BL/6 mice infected intravenously with 106 CFU of C. neoformans strain 52D [58]. Using this model, we found that infected mice displayed overt and severe symptoms similar to that of human patients, including increased cranial pressure, ataxia, and limb paralysis after 21 days post infection (dpi). Importantly, over 50% of animals succumbed to infection between 21 and 35 dpi, despite apparent fungal control in the CNS (Figure 1). Thus, we showed that the magnitude of CNS fungal burden does not directly correlate with the intensity of disease symptoms or mortality during CM.

Figure 1.

Depletion of CD4+ T cells resulted in improved survival despite higher fungal burden during CM. C57BL/6 mice were infected with 106 CFU of C. neoformans 52D via retro-orbital intravenous inoculation. (A) Fungal burdens were measured in whole-brain homogenates at the indicated time points. Naive mice and animals that succumbed to infection (†) are indicated. (B) Representative images of severe cranial swelling and CNS tissue injury in infected mice. (C) Survival of infected CD4-depleted (broken line) and isotype-treated mice through 35 dpi. (D) Brain fungal burdens were calculated on day 21 and 35 dpi. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Reproduced from Neal et al., [58].

Brain cellular inflammation, marked by leukocyte accumulation after 21 dpi and dominated by CD4+ T cell infiltration, plays an important role in the pathology of the CNS in cryptococcal-infected mice. Similar to human patients with IRIS and PIIRS, infiltrating CD4+ T cells in brains of cryptococcal-infected mice exhibit a Th1-type bias and produce high levels of IFN-γ. Critically, the influx of immune cells into the CNS after 21 dpi was synchronized with the onset of fungal clearance, development of neurological symptoms, and mortality. The depletion of CD4 + T cells leads to a reduction in mortality and inflammatory pathology, providing conceptual evidence that CD4 + T cells are a principal mediator of inflammation and pathology in this model. Notably, over the course of the study, the survival of CD4+ T cell depleted mice significantly improved despite having higher fungal loads in the CNS compared to mice with sufficient CD4+ T cells (Figure 1). Depletion of CD4+ T cells during CM also broadly inhibited all other aspects of the CNS inflammatory response, including accumulation of CD8+ T cells and CD11b + Ly6C+ myeloid effector cells. Taken together, these data strongly support the idea that CD4+ T cells exert dual but opposing roles during CM: promoting the elimination of the fungal pathogen in the CNS but simultaneously driving tissue damage, neurological deterioration, and death.

Another animal model has also demonstrated the pathological role of CD4+ T cells in cIRIS. Eschke and colleagues reconstituted RAG−/− mice, which are deficient in T and B cells, with WT CD4+ T cells after infection with C. neoformans [59]. They found that mice receiving CD4 T cells displayed high levels of Th1-type cytokines such as TNF-α and IFN-γ compared to mice not receiving CD4+ T cells. These results suggested that CD4+ T cell reconstitution in mice infected with C. neoformans may lead to syndromes similar to IRIS in HIV-infected patients [59]. These animal models provide important tools for further investigating the mechanism of cryptococcal pathology.


5. Host immunity to C. neoformans infection: protective or non-protective, the yin and yang

Protective immunity is conferred by a fine balance between immune responses that eliminate the pathogen and those that limit host damages. However, an immune response induced by the pathogen may be non-protective for any one or combination of the following reasons: (1) it could occur in the wrong location or timeframe, promoting inflammatory injury without effective clearance of pathogens; (2) it could be too strong and cause immunopathology despite control of pathogen burden; 3) regulatory mechanisms meant to maintain host tissue integrity may lead to microbial survival and persistence and thus result in chronic inflammation. Below, we describe cellular and molecular mechanisms by which dysregulation of immune responses contribute to host disease during infection with C. neoformans.

5.1 Host immune responses contribute to fungal clearance but also tissue damage

Upon infection, C. neoformans is sensed by a variety of innate receptors including Toll-like receptors [60, 61, 62], mannose receptors [60], and β-glucan receptors [63, 64, 65]. Macrophages [66, 67], DCs [68], natural killer cells [69, 70, 71, 72] and neutrophils [73] have been shown to mediate killing C. neoformans, however, the development of the adaptive immune response is required for controlling the fungal growth in the host [74, 75, 76]. Specifically, the development of Th1 and Th17 responses that are associated with classical activation of macrophages (M1) promotes fungal clearance in both humans and experimental mouse models [14, 77]. DCs and macrophages function as the potential sensors for infection through PRRs or inflammasomes, and produce cytokines such as IL-12, IL-23, IL-6, IL-18, TNF-α and IL-1β, which have been shown to promote the Th1/Th17 response during C. neoformans infection [78, 79, 80, 81, 82, 83, 84]. During this response, Th1 and Th17 cells produce cytokines such as IFN-γ, IL-17 and IL-22, which act on macrophages, neutrophils or epithelial cells and induce robust antimicrobial and phagocytic responses, including the production of reactive oxygen and nitrogen species [16, 85, 86, 87, 88, 89, 90]. As a result, resident and/or recruited macrophages and DCs can become highly activated and function as the main effector cells for controlling fungal infection [91, 92].

Although generation of the Th1/Th17 response and subsequent M1 activation play a critical role in controlling fungal growth, excessive immune responses can become destructive and cause lung immunopathology following fungal infection. Recent studies demonstrated that FADD and RIPK3 proteins, which are mediators of death receptor-triggered extrinsic apoptosis, play a crucial immune regulatory role in preventing excessive inflammation during C. neoformans infection [93]. Deletion of RIPK3 and FADD led to a robust Th1-biased response with M1-biased macrophage activation, which is accompanied by marked upregulation of cytokines like TNF-α, IL-1α, IL-1β, IL6, and IFN-γ (Figure 2). Rather than being protective, this robust host response was deleterious and is associated with paradoxical fungal growth and rapid clinical deterioration (Figure 2). These findings showed that excessive inflammation can mediate tissue damage and host disease during cryptococcal infection [93]. Furthermore, the balance between Th1 and Th17 immune responses plays important roles in optimizing clearance and minimizing inflammatory damage to the host tissues during fungal infections. For example, it has been shown that IL-23 and Th17 pathway act as a negative regulator of Th1 response and thus contribute to fungal growth during C. albicans and A. fumigatus infection [94]. Recent studies show that the Th1, Th2, Th17 responses and cytokines co-exist and evolve during different time points in a chronic fungal infection [13], while fungus adapts to and exploit the dysregulation of this immune balance. Thus, therapeutic cytokines and vaccines may create a new therapeutic mean to restore protective host responses and fungal control, but would need to be introduced with extreme caution not to induce an excessive immune bias.

Figure 2.

RIPK3 and FADD modulate host responses against C. neoformans infection. (A) Ripk3−/− and Ripk3−/−Fadd−/− mice were more susceptible to C. neoformans infection. (B) Diminished fungal clearance in lungs of Ripk3−/− and Ripk3−/−Fadd−/− mice. (C) RIPK3 or FADD deletions altered Th-polarizing and pro-inflammatory cytokine profiles in pulmonary response to cryptococcal infection. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. Reproduced from Fa et al., [93].

DCs play a critical role in modulating host antifungal responses. Distinct PRRs and intracellular signaling pathways in DCs help to define the immune response to fungal pathogens [95]. Studies from Bonifazi et al. showed that C. albicans exploits multiple, functionally distinct, receptor-signaling pathways in DCs ultimately affecting the local inflammatory/anti-inflammatory state in the gut [96]. Furthermore, depletion of DC through administration of diphtheria toxin to transgenic mice resulted in rapid clinical deterioration and death of mice infected with C. neoformans [97]. Early mortality in DC-depleted mice was related to increased neutrophil accumulation accompanied with histopathologic evidence of alveolar damage, including hemorrhagic and proteinaceous exudates [97]. Similar changes mediated by neutrophils were associated with respiratory failure and death [98]. Collectively, these data define an important role for DC in regulating the initial innate and adaptive response following fungal infections.

5.2 Host immune responses normally associated with homeostasis can contribute to fungal persistence

Cryptococcal virulence includes evasion of immune recognition, interference with phagocytosis, and modulation of host immune responses [56, 99]. Many fungal factors have been shown to promote allergic Th2 or Treg responses. These types of responses are characterized by alternatively activated macrophages and may promote uncontrolled fungal growth [56]. However, the regulatory immune response is also crucial for maintaining host tissue homeostasis and limiting the inflammatory responses that can cause tissue damage.

Th2: In murine models, C. neoformans exhibits a remarkable ability to induce Th2 response, which is associated with fungal growth, fungus-associated allergic responses and disease relapse. Although rare for C. neoformans infection, other fungal pathogens such as Aspergillus fumigatus can induce devastating allergic bronchopulmonary mycosis in human patients that is accompanied by a Th2 response [100, 101]. Additionally, enhancing the Th2 response in a mouse model has been shown to exacerbate pulmonary disease during cryptococcal infection, supporting a causal role of Th2 response in pathology [102].

IL-4 and IL-13 provide the most potent proximal signals for Th2 cell polarization [13, 17, 103]. The epithelial-derived cytokines thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 have been shown to regulate the development of Th2 response during asthma [104, 105]. A time-dependent increase in IL-33 expression in the lungs has been found during C. neoformans infection, and IL-33 signaling can promote Th2 response and facilitates cryptococcal growth in the lungs [106]. In addition, chitin recognition via host chitotriosidase promotes harmful Th2 cell differentiation by CD11b + conventional DCs in response to pulmonary fungal infection [102]. However, Th2 polarization may play beneficial roles at certain stage of infection. IL-4Ra has been shown to afford protection early upon infection associated with increased IFN-γ and nitric oxide production. More importantly, Th2 response plays important roles in wound healing to tissue destructive pathogens [107] and down regulating inflammatory responses [108]. Many of the proteins produced in response to IL-4 and IL-13, such as arginase, MMP12, and TREM-2, are associated with injury [109]. Th2-activated macrophages also produce TGF-β which can suppress pro-inflammatory responses while at the same time serving as a potent pro-fibrotic mediator [110].

Treg: CD4+ CD25+ Treg cells expressing the transcription factor forkhead box protein 3 (FoxP3) play critical roles in down-regulating immune responses and promoting homeostasis [111, 112]. Accumulation of antigen specific Treg has been shown during infection with fungal pathogens [113, 114, 115, 116]. Multiple studies have shown that Treg can suppress effector cells and lead to fungal persistence. For example, Treg in mice infected with C. albicans were shown to be capable of inhibiting Th1 activity, thereby limiting protective responses. However, the roles of Treg in modulating Th17 activity are still controversial, with both positive and negative effects reported [117, 118]. Similar enhancement of effector function in the absence of Treg can be found in multiple other models of viral, bacterial, and parasitic infection [119].

While Treg may lead to pathogen persistence, they can actually be beneficial in protecting against immune-mediated damage to the host. This has been demonstrated in diseases caused by Pneumocystis pneumonia, HSV, Schistosoma mansoni where depletion of Treg leads to enhanced pathology [120, 121, 122, 123]. It has been shown that depletion of Tregs enhanced Th2 response during pulmonary cryptococcal infection as evidenced by increased mucus production, enhanced eosinophilia, and increased IgE production [113]. Interestingly, Treg-depleted mice exhibited elevated fungal burden compared to control mice, suggesting that Treg mediated enhanced fungal control by inhibiting non-protective Th2 responses [113]. Confirming these observations, therapeutic expansion of Tregs during pulmonary cryptococcal infection has been shown to limit allergic airway inflammation, as demonstrated by reduced production of IgE and Th2 cytokines [116, 124]. Since laboratory mice show a strong tendency to develop a detrimental Th2 response during C. neoformans infection, Tregs may be protective in this context by inhibiting the tissue-damaging Th2 response. Furthermore, Tregs have also been demonstrated to be required for resistance to reinfection with C. albicans [120].

IL-10 is a critical effector molecule involved in the immunoregulatory functions of Treg cells [125]. IL-10 has been reported to inhibit production of cytokines such as IL-1, IL-6, IL-23, IFN-γ, TNF-α and chemokines including CCL2(MCP-1), CCL12(MCP-5), CCL5(RANTES), IL-8, CXCL10(IP-10), and CXCL2(MIP-2) [126]. During C. neoformans infection, IL-10-deficient mice display reduced expression of IL-4, IL-5, and IL-13, but enhanced TNF-α and IL-12 expression [127]. Studies have further shown that IL-10 signaling blockade can promote fungal control even if administered after persistent infection has been established [128]. IL-10 expression also occurs and dampens fungal control in response to other fungal pathogens such as C. albicans, H. capsulatum and A. fumigatus [129, 130, 131]. These studies suggest that IL-10 production plays an essential role in the development of persistent fungal infections. Deficiency or blockade of IL-10 may result in better fungal control, however, it comes at the cost of excessive inflammation that may cause greater tissue damage [127, 132, 133].

The roles of Tregs in the CNS during fungal infection, however, remain less studied. One report shows an increase in the abundance of Treg cells within cIRIS patients [134]. Further clinical and animal studies are needed to investigate the functions of Tregs during fungal CNS infections.


6. Conclusions and future directions

A tightly-regulated balance between inflammatory and regulatory mechanisms is required to control fungal infection, maintain host homeostasis, and ultimately develop protective immunity (Figure 3). Recent studies have demonstrated that disease and mortality in cryptococcal infection can result from either uncontrolled fungal growth due to defective host immunity, or excessive host inflammation. As the spectrum of hosts with cryptococcal disease expands, it is critical to understand and distinguish pathology caused by the pathogen or host responses. For example, additional suppression of weak immunity by steroid therapy in patients with uncontrolled fungal growth may lead to enhanced fungus-mediated damage and mortality in HIV-associated cryptococcal patients [135]. Instead, adjunctive IFN-γ therapy to bolstering immunity in these patients has the potential to ameliorate fungus-mediated damage and mortality [136]. However, in cIRIS patients, who experience inflammation-mediated tissue damage and mortality, corticosteroids can be effective to control disease-related deterioration [30]. Furthermore, mounting evidence implies that the top priority for cIRIS and PIIRS is to control the devastating immunopathology. Thus, comprehensive therapeutic strategies that take fungus- and host mediated damage into account could have the potential to significantly improve therapeutic outcomes.

Figure 3.

C. neoformans and host interactions determine disease outcomes. In the center, innate immune cells such as DCs recognize C. neoformans using multiple pattern recognition receptors. A weak immune response due to HIV, cancer, or organ transplant can result in fungal-mediated tissue damage. Macrophages recruited into the infected tissue without T cell stimulation fail to control fungal growth. In healthy individuals, the DC-initiated Th1 response, which completely activated macrophages to efficiently control C. neoformans infection. Cytokines such as TNF-α and IFN-γ, as well as iNOS, are critical for fungal control. Tregs play important roles in limiting inflammation and maintaining homeostasis of the host. During IRIS and PIIRS, however, excessive inflammation can cause tissue damage despite fungal control. Whether Tregs are functional under this state is not clear. Macrophages may not be activated in PIIRS patients even with strong Th1 and IFN-γ production. Overproduction of cytokines and iNOS may promote tissue damage and cause disease. For certain host genetic backgrounds or highly virulent strains, an allergic Th2 response is developed and control of fungal growth fails. Host tissue damage in this circumstance may stem from both the pathogen and the detrimental Th2 responses.

Recent studies have identified the involvement of a number of immunopathogenic mechanisms including CD4+ T cells. However, the function of CD4 T cells overlaps with the mechanisms required for fungal clearance. Little is known about whether it is possible to uncouple the anti-fungal host defense mechanisms from the host immune responses that mediate deleterious immunopathology. One of the future directions in this research field is to identify mechanisms that are not required for fungal clearance but are major culprits in immunopathology which could be promising targets for future immunotherapies.



The authors thank Mr. Mack Reynolds for thoughtful edit of the manuscript.

This work was supported in part by the Intramural Research Program of the NIH, NIAID, AI001123-01 and AI001124-01 to PRW and Veterans Administration Merit Review Awards to M.A.O. (1I01BX000656) and VA RCS Award M.A.O. (1IK6BX003615).


Conflict of interest

The authors declare that there is no conflict of interest regarding the publication of this article.


  1. 1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525-530
  2. 2. Pappas PG. Cryptococcal infections in non-HIV-infected patients. Transactions of the American Clinical and Climatological Association. 2013;124:61
  3. 3. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis. The Lancet Infectious Diseases. 2017;17:873-881
  4. 4. González-Duarte A, Calleja JH, Mitre VG, Ramos GG. Simultaneous central nervous system complications of C. neoformans infection. Neurology International. 2009;1:e22
  5. 5. Goldberg DW, Tenforde MW, Mitchell HK, Jarvis JN. Neurological sequelae of adult meningitis in Africa: A systematic literature review. In: Open Forum Infectious Diseases. USA: Oxford University Press; 2017. p. ofx246
  6. 6. Beardsley J, Wolbers M, Kibengo FM, Ggayi A-BM, Kamali A, Cuc NTK, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. New England Journal of Medicine. 2016;374:542-554
  7. 7. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: The role of fluconazole resistance and immune reconstitution. Clinical Infectious Diseases. 2006;43:1069-1070
  8. 8. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Clinical Infectious Diseases. 2000;30:710-718
  9. 9. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2010;50:291-322
  10. 10. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clinical Infectious Diseases. 2001;33:690-699
  11. 11. Lee Y-C, Wang J-T, Sun H-Y, Chen Y-C. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. Journal of Microbiology, Immunology and Infection. 2011;44:338-345
  12. 12. Musubire AK, Boulware DR, Meya DB, Rhein J. Diagnosis and management of cryptococcal relapse. Journal of AIDS & Clinical Research. 2013;Suppl 3(3). pii: S3-003
  13. 13. Arora S, Olszewski MA, Tsang TM, McDonald RA, Toews GB, Huffnagle GB. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptococcus neoformans. Infection and Immunity. 2011;79(5):1915-1926
  14. 14. Chen G-h, McNamara DA, Hernandez Y, Huffnagle GB, Toews GB, Olszewski MA. Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infection and Immunity. 2008;76:2379-2391
  15. 15. Jain AV, Zhang Y, Fields WB, McNamara DA, Choe MY, Chen G-h, et al. Th2 but not Th1 immune bias results in altered lung functions in a murine model of pulmonary Cryptococcus neoformans infection. Infection and Immunity. 2009;77:5389-5399
  16. 16. Murdock BJ, Huffnagle GB, Olszewski MA, Osterholzer JJ. Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production. Infection and Immunity. 2014;82:937-948
  17. 17. Zhang Y, Wang F, Tompkins KC, McNamara A, Jain AV, Moore BB, et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. The American Journal of Pathology. 2009;175:2489-2500
  18. 18. Hardison SE, Ravi S, Wozniak KL, Young ML, Olszewski MA, Wormley FL Jr. Pulmonary infection with an interferon-γ-producing Cryptococcus neoformans strain results in classical macrophage activation and protection. The American Journal of Pathology. 2010;176:774-785
  19. 19. Wozniak KL, Ravi S, Macias S, Young ML, Olszewski MA, Steele C, et al. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One. 2009;4:e6854
  20. 20. Wozniak KL, Young ML, Wormley FL. Protective immunity against experimental pulmonary cryptococcosis in T cell depleted mice. Clinical and Vaccine Immunology. 2011;18(5):717-723
  21. 21. Huffnagle GB, McNeil LK. Dissemination of C. neoformans to the central nervous system: Role of chemokines, Th1 immunity and leukocyte recruitment. Journal of Neurovirology. 1999;5:76-81
  22. 22. Uicker WC, McCracken JP, Buchanan KL. Role of CD4+ T cells in a protective immune response against Cryptococcus neoformans in the central nervous system. Sabouraudia. 2006;44:1-11
  23. 23. Aguirre K, Crowe J, Haas A, Smith J. Resistance to Cryptococcus neoformans infection in the absence of CD4+ T cells. Medical Mycology. 2004;42:15-25
  24. 24. Uicker WC, Doyle HA, McCracken JP, Langlois M, Buchanan KL. Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Medical Mycology. 2005;43:27-38
  25. 25. Buchanan KL, Doyle HA. Requirement for CD4+ T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infection and Immunity. 2000;68:456-462
  26. 26. Pirofski L-a, Casadevall A. Immune-mediated damage completes the parabola: Cryptococcus neoformans pathogenesis can reflect the outcome of a weak or strong immune response. MBio. 2017;8:e02063-e02017
  27. 27. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kambugu A, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. The Journal of Infectious Diseases. 2010;202:962-970
  28. 28. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: Proposed clinical case definitions. The Lancet Infectious Diseases. 2010;10:791-802
  29. 29. Panackal AA, Komori M, Kosa P, Khan O, Hammoud DA, Rosen LB, et al. Spinal arachnoiditis as a complication of cryptococcal meningoencephalitis in non-HIV previously healthy adults. Clinical Infectious Diseases. 2017;64:275-283
  30. 30. Panackal AA, Wuest SC, Lin YC, Wu T, Zhang N, Kosa P, et al. Paradoxical immune responses in non-HIV cryptococcal meningitis. PLoS Pathogens. 2015;11:e1004884
  31. 31. Williamson PR. Post-infectious inflammatory response syndrome (PIIRS): Dissociation of T-cell-macrophage signaling in previously healthy individuals with cryptococcal fungal meningoencephalitis. Macrophage (Houst). 2015;2:pii: e1078
  32. 32. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: The trouble with immunity when you had none. Nature Reviews. Microbiology. 2012;10:150-156
  33. 33. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective cohort study. PLoS Medicine. 2010;7:e1000384
  34. 34. Chang CC, Omarjee S, Lim A, Spelman T, Gosnell BI, Carr WH, et al. Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. The Journal of Infectious Diseases. 2013;208:1604-1612
  35. 35. Meya DB, Manabe YC, Boulware DR, Janoff EN. The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: Understanding a conundrum. Current Opinion in Infectious Diseases. 2016;29:10-22
  36. 36. Meya DB, Okurut S, Zziwa G, Rolfes MA, Kelsey M, Cose S, et al. Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. The Journal of Infectious Diseases. 2015;211:1597-1606
  37. 37. Panackal AA, Marr KA, Williamson PR. Dexamethasone in cryptococcal meningitis. The New England Journal of Medicine. 2016;375:188
  38. 38. Casadevall A, Pirofski L-a. Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity. Infection and Immunity. 1999;67:3703-3713
  39. 39. Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningoencephalitis: Analysis of 27 patients with pathogenetic implications. Human Pathology. 1996;27:839-847
  40. 40. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, Zhou H, et al. Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. The Journal of Clinical Investigation. 2010;120:1683-1693
  41. 41. Vu K, Tham R, Uhrig JP, Thompson GR, Pombejra SN, Jamklang M, et al. Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. MBio. 2014;5:e01101-e01114
  42. 42. Olszewski MA, Noverr MC, Chen G-H, Toews GB, Cox GM, Perfect JR, et al. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. The American Journal of Pathology. 2004;164:1761-1771
  43. 43. Bratton EW, El Husseini N, Chastain CA, Lee MS, Poole C, Stürmer T, et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One. 2012;7:e43582
  44. 44. Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One. 2013;8:e60431
  45. 45. Jarvis JN, Meintjes G, Bicanic T, Buffa V, Hogan L, Mo S, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. PLoS Pathogens. 2015;11:e1004754
  46. 46. Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, Levitz SM, et al. The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. The Journal of Infectious Diseases. 2013;207:1817-1828
  47. 47. Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A, et al. Cryptococcal meningitis: Epidemiology, immunology, diagnosis and therapy. Nature Reviews Neurology. 2017;13:13
  48. 48. Sun H-Y, Alexander BD, Huprikar S, Forrest GN, Bruno D, Lyon GM, et al. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: Implications for the management of immunosuppression. Clinical Infectious Diseases. 2014;60:36-44
  49. 49. Worsley CM, Suchard MS, Stevens WS, Van Rie A, Murdoch DM. Multi-analyte profiling of ten cytokines in South African HIV-infected patients with immune reconstitution inflammatory syndrome (IRIS). AIDS Research and Therapy. 2010;7:36
  50. 50. Krupica T Jr, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: A two-hit model. Clinical Immunology. 2006;120:121-128
  51. 51. Meya DB, Okurut S, Zziwa G, Rolfes MA, Kelsey M, Cose S, et al. Cellular immune activation in cerebrospinal fluid from Ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome. The Journal of Infectious Diseases. 2014;211:1597-1606
  52. 52. Scriven JE, Rhein J, Hullsiek KH, Von Hohenberg M, Linder G, Rolfes MA, et al. Early ART after cryptococcal meningitis is associated with cerebrospinal fluid pleocytosis and macrophage activation in a multisite randomized trial. The Journal of Infectious Diseases. 2015;212:769-778
  53. 53. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2000;47:707-717
  54. 54. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Research Reviews. 2005;48:185-195
  55. 55. Nikić I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nature Medicine. 2011;17:495
  56. 56. Olszewski MA, Zhang Y, Huffnagle GB. Mechanisms of cryptococcal virulence and persistence. Future Microbiology. 2010;5:1269-1288
  57. 57. Fang W, Fa Z, Liao W. Epidemiology of Cryptococcus and cryptococcosis in China. Fungal Genetics and Biology. 2015;78:7-15
  58. 58. Neal LM, Xing E, Xu J, Kolbe JL, Osterholzer JJ, Segal BM, et al. CD4+ T cells orchestrate lethal immune pathology despite fungal clearance during Cryptococcus neoformans meningoencephalitis. MBio. 2017;8:e01415-e01417
  59. 59. Eschke M, Piehler D, Schulze B, Richter T, Grahnert A, Protschka M, et al. A novel experimental model of Cryptococcus neoformans-related immune reconstitution inflammatory syndrome (IRIS) provides insights into pathogenesis. European Journal of Immunology. 2015;45:3339-3350
  60. 60. Dan JM, Wang JP, Lee CK, Levitz SM. Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLoS One. 2008;3:e2046
  61. 61. Nakamura K, Miyazato A, Xiao G, Hatta M, Inden K, Aoyagi T, et al. Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. The Journal of Immunology. 2008;180:4067-4074
  62. 62. Biondo C, Midiri A, Messina L, Tomasello F, Garufi G, Catania MR, et al. MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans. European Journal of Immunology. 2005;35:870-878
  63. 63. Nakamura K, Kinjo T, Saijo S, Miyazato A, Adachi Y, Ohno N, et al. Dectin-1 is not required for the host defense to Cryptococcus neoformans. Microbiology and Immunology. 2007;51:1115-1119
  64. 64. Campuzano A, Castro-Lopez N, Wozniak KL, Wager CML, Wormley FL Jr. Dectin-3 is not required for protection against Cryptococcus neoformans infection. PLoS One. 2017;12:e0169347
  65. 65. Cross C, Bancroft G. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form. Infection and Immunity. 1995;63:2604-2611
  66. 66. Vecchiarelli A, Pietrella D, Dottorini M, Monari C, Retini C, Todisco T, et al. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clinical & Experimental Immunology. 1994;98:217-223
  67. 67. Liu L, Tewari RP, Williamson PR. Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages. Infection and Immunity. 1999;67:6034-6039
  68. 68. Wozniak KL, Levitz SM. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infection and Immunity. 2008;76:4764-4771
  69. 69. Kawakami K, Koguchi Y, Qureshi MH, Yara S, Kinjo Y, Uezu K, et al. NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18. Microbiology and Immunology. 2000;44:1043-1050
  70. 70. Wiseman JC, Ma LL, Marr KJ, Jones GJ, Mody CH. Perforin-dependent cryptococcal microbicidal activity in NK cells requires PI3K-dependent ERK1/2 signaling. The Journal of Immunology. 2007;178:6456-6464
  71. 71. Xiang RF, Li S, Ogbomo H, Stack D, Mody CH. β1 Integrins are required to mediate NK cell killing of Cryptococcus neoformans. The Journal of Immunology. 2018;201:2369-2376
  72. 72. Li SS, Mody CH. NKp46 is an NK cell fungicidal pattern recognition receptor. Trends in Microbiology. 2016;24:929-931
  73. 73. Chaturvedi V, Wong B, Newman SL. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. The Journal of Immunology. 1996;156:3836-3840
  74. 74. Mody C, Lipscomb M, Street N, Toews G. Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. The Journal of Immunology. 1990;144:1472-1477
  75. 75. Lim T, Murphy J. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infection and Immunity. 1980;30:5-11
  76. 76. Mody CH, Paine R, Jackson C, Chen G-H, Toews GB. CD8 cells play a critical role in delayed type hypersensitivity to intact Cryptococcus neoformans. The Journal of Immunology. 1994;152:3970-3979
  77. 77. Romani L. Immunity to fungal infections. Nature Reviews Immunology. 2011;11:275
  78. 78. Kleinschek MA, Muller U, Brodie SJ, Stenzel W, Kohler G, Blumenschein WM, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. The Journal of Immunology. 2006;176:1098-1106
  79. 79. Kawakami K, Tohyama M, Xie Q , Saito A. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clinical & Experimental Immunology. 1996;104:208-214
  80. 80. Kawakami K, Qureshi MH, Zhang T, Okamura H, Kurimoto M, Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. The Journal of Immunology. 1997;159:5528-5534
  81. 81. Siddiqui AA, Shattock RJ, Harrison TS. Role of capsule and interleukin-6 in long-term immune control of Cryptococcus neoformans infection by specifically activated human peripheral blood mononuclear cells. Infection and Immunity. 2006;74:5302-5310
  82. 82. Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. The Journal of Immunology. 1996;157:4529-4536
  83. 83. Shourian M, Ralph B, Angers I, Sheppard DC, Qureshi ST. Contribution of IL-1RI signaling to protection against Cryptococcus neoformans 52D in a mouse model of infection. Frontiers in Immunology. 2018;8:1987
  84. 84. Chen M, Xing Y, Lu A, Fang W, Sun B, Chen C, et al. Internalized Cryptococcus neoformans activates the canonical caspase-1 and the noncanonical caspase-8 inflammasomes. The Journal of Immunology. 2015;195(10):4962-4972
  85. 85. Flesch I, Schwamberger G, Kaufmann S. Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans. The Journal of Immunology. 1989;142:3219-3224
  86. 86. Chen G-H, McDonald RA, Wells JC, Huffnagle GB, Lukacs NW, Toews GB. The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infection and Immunity. 2005;73:1788-1796
  87. 87. Wager CML, Hole CR, Campuzano A, Castro-Lopez N, Cai H, Van Dyke MCC, et al. IFN-γ immune priming of macrophages in vivo induces prolonged STAT1 binding and protection against Cryptococcus neoformans. PLoS Pathogens. 2018;14:e1007358
  88. 88. Wozniak KL, Hardison SE, Kolls JK, Wormley FL Jr. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS One. 2011;6:e17204
  89. 89. Wozniak KL, Hole CR, Yano J, Fidel PL Jr, Wormley FL Jr. Characterization of IL-22 and antimicrobial peptide production in mice protected against pulmonary Cryptococcus neoformans infection. Microbiology. 2014;160:1440-1452
  90. 90. Aguirre K, Gibson G. Differing requirement for inducible nitric oxide synthase activity in clearance of primary and secondary Cryptococcus neoformans infection. Medical Mycology. 2000;38:343-353
  91. 91. Osterholzer JJ, Chen G-H, Olszewski MA, Zhang Y-M, Curtis JL, Huffnagle GB, et al. Chemokine receptor 2-mediated accumulation of fungicidal exudate macrophages in mice that clear cryptococcal lung infection. The American Journal of Pathology. 2011;178:198-211
  92. 92. Espinosa V, Jhingran A, Dutta O, Kasahara S, Donnelly R, Du P, et al. Inflammatory monocytes orchestrate innate antifungal immunity in the lung. PLoS Pathogens. 2014;10:e1003940
  93. 93. Fa Z, Xie Q , Fang W, Zhang H, Xu J, Pan W, et al. RIPK3/Fas-associated death domain Axis regulates pulmonary Immunopathology to Cryptococcal infection independent of Necroptosis. Frontiers in Immunology. 2017;8:1055
  94. 94. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti S, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. European Journal of Immunology. 2007;37:2695-2706
  95. 95. Eastman AJ, Osterholzer JJ, Olszewski MA. Role of dendritic cell-pathogen interactions in the immune response to pulmonary cryptococcal infection. Future Microbiology. 2015;10:1837-1857
  96. 96. Bonifazi P, Zelante T, D'angelo C, De Luca A, Moretti S, Bozza S, et al. Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunology. 2009;2:362
  97. 97. Osterholzer JJ, Milam JE, Chen G-H, Toews GB, Huffnagle GB, Olszewski MA. Role of dendritic cells and alveolar macrophages in regulating early host defense against pulmonary infection with Cryptococcus neoformans. Infection and Immunity. 2009;77:3749-3758
  98. 98. Abraham E. Neutrophils and acute lung injury. Critical Care Medicine. 2003;31:S195-S199
  99. 99. Esher SK, Zaragoza O, Alspaugh JA. Cryptococcal pathogenic mechanisms: A dangerous trip from the environment to the brain. Memórias do Instituto Oswaldo Cruz. 2018;113(7):e180057
  100. 100. Arora S, Huffnagle GB. Immune regulation during allergic bronchopulmonary mycosis. Immunologic Research. 2005;33:53-68
  101. 101. Greenberger PA, Bush RK, Demain JG, Luong A, Slavin RG, Knutsen AP. Allergic bronchopulmonary aspergillosis. The Journal of Allergy and Clinical Immunology: In Practice. 2014;2:703-708
  102. 102. Wiesner DL, Specht CA, Lee CK, Smith KD, Mukaremera L, Lee ST, et al. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathogens. 2015;11:e1004701
  103. 103. Müller U, Stenzel W, Köhler G, Werner C, Polte T, Hansen G, et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. The Journal of Immunology. 2007;179:5367-5377
  104. 104. Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: Epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunological Reviews. 2008;226:172-190
  105. 105. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: The new kid in the IL-1 family. Nature Reviews Immunology. 2010;10:103
  106. 106. Flaczyk A, Duerr CU, Shourian M, Lafferty EI, Fritz JH, Qureshi ST. IL-33 signaling regulates innate and adaptive immunity to Cryptococcus neoformans. The Journal of Immunology. 2013;191(5):2503-2513
  107. 107. Allen JE, Wynn TA. Evolution of Th2 immunity: A rapid repair response to tissue destructive pathogens. PLoS Pathogens. 2011;7:e1002003
  108. 108. Arendse B, Schwegmann A, Radwanska M, Leeto M, Kirsch R, Hall P, et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity. 2004;21:455
  109. 109. Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, Allison JP, et al. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. The Journal of Immunology. 2007;179:3926-3936
  110. 110. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22 in immunity and autoimmunity. Current Opinion in Pharmacology. 2009;9:447-453
  111. 111. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annual Review of Immunology. 2004;22:531-562
  112. 112. Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009;31:401-411
  113. 113. Schulze B, Piehler D, Eschke M, von Buttlar H, Kohler G, Sparwasser T, et al. CD4(+) FoxP3(+) regulatory T cells suppress fatal T helper 2 cell immunity during pulmonary fungal infection. European Journal of Immunology. 2014;44:3596-3604
  114. 114. Netea MG, Sutmuller R, Hermann C, Van der Graaf CA, Van der Meer JW, Van Krieken JH, et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. The Journal of Immunology. 2004;172:3712-3718
  115. 115. Montagnoli C, Fallarino F, Gaziano R, Bozza S, Bellocchio S, Zelante T, et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. The Journal of Immunology. 2006;176:1712-1723
  116. 116. Wiesner DL, Smith KD, Kotov DI, Nielsen JN, Bohjanen PR, Nielsen K. Regulatory T cell induction and retention in the lungs drives suppression of detrimental type 2 Th cells during pulmonary cryptococcal infection. Journal of Immunology. 2016;196:365-374
  117. 117. De Luca A, Montagnoli C, Zelante T, Bonifazi P, Bozza S, Moretti S, et al. Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. The Journal of Immunology. 2007;179:5999-6008
  118. 118. Whibley N, MacCallum DM, Vickers MA, Zafreen S, Waldmann H, Hori S, et al. Expansion of Foxp3+ T-cell populations by Candida albicans enhances both Th17-cell responses and fungal dissemination after intravenous challenge. European Journal of Immunology. 2014;44:1069-1083
  119. 119. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions. Annual Review of Immunology. 2009;27:551-589
  120. 120. Montagnoli C, Bacci A, Bozza S, Gaziano R, Mosci P, Sharpe AH, et al. B7/CD28-dependent CD4+ CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. The Journal of Immunology. 2002;169:6298-6308
  121. 121. McKinley L, Logar AJ, McAllister F, Zheng M, Steele C, Kolls JK. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia. The Journal of Immunology. 2006;177:6215-6226
  122. 122. Hesse M, Piccirillo CA, Belkaid Y, Prufer J, Mentink-Kane M, Leusink M, et al. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. The Journal of Immunology. 2004;172:3157-3166
  123. 123. Guilliams M, Oldenhove G, Noel W, Hérin M, Brys L, Loi P, et al. African trypanosomiasis: Naturally occurring regulatory T cells favor trypanotolerance by limiting pathology associated with sustained type 1 inflammation. The Journal of Immunology. 2007;179:2748-2757
  124. 124. Schulze B, Piehler D, Eschke M, Heyen L, Protschka M, Köhler G, et al. Therapeutic expansion of CD4+ FoxP3+ regulatory T cells limits allergic airway inflammation during pulmonary fungal infection. FEMS Pathogens and Disease. 2016;74:ftw020
  125. 125. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nature Reviews Immunology. 2008;8:523
  126. 126. Couper KN, Blount DG, Riley EM. IL-10: The master regulator of immunity to infection. The Journal of Immunology. 2008;180:5771-5777
  127. 127. Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. The Journal of Immunology. 2005;174:1027-1036
  128. 128. Murdock BJ, Teitz-Tennenbaum S, Chen GH, Dils AJ, Malachowski AN, Curtis JL, et al. Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infection. Journal of Immunology. 2014;193:4107-4116
  129. 129. Vazquez-Torres A, Jones-Carson J, Wagner RD, Warner T, Balish E. Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. Infection and Immunity. 1999;67:670-674
  130. 130. Sahaza JH, Suárez-Alvarez R, Estrada-Bárcenas DA, Pérez-Torres A, Taylor ML. Profile of cytokines in the lungs of BALB/c mice after intra-nasal infection with Histoplasma capsulatum mycelial propagules. Comparative Immunology, Microbiology and Infectious Diseases. 2015;41:1-9
  131. 131. Mirkov I, Demenesku J, Aleksandrov AP, Ninkov M, Glamoclija J, Kataranovski D, et al. Strain differences in the immune mechanisms of resistance of immunocompetent rats to pulmonary aspergillosis. Immunobiology. 2015;220:1075-1084
  132. 132. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274
  133. 133. Hoshi N, Schenten D, Nish SA, Walther Z, Gagliani N, Flavell RA, et al. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nature Communications. 2012;3:1120
  134. 134. Tan D, Yong Y, Tan H, Kamarulzaman A, Tan L, Lim A, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Medicine. 2008;9:307-316
  135. 135. Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. The New England Journal of Medicine. 2016;374:542-554
  136. 136. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: A randomized controlled trial. AIDS. 2012;26:1105-1113

Written By

Jintao Xu, Peter R. Wiliamson and Michal A. Olszewski

Submitted: October 23rd, 2018 Reviewed: December 21st, 2018 Published: March 1st, 2019